Concise summaries of key terms, topics, or policies for subscribers on pharma, biotech, business, and policy.
Our team is known for policy analysis, particularly evidence-based analysis, which we publish as inferences.
Deep dives into topics on pharmaceutical policies, regulations, and economics in biotech
Stay up to date with the latest biotech data analytic news
The Department of Health and Human Services Centers for Medicare and Medicaid Services (CMS) recently released initial g...
This article will focus on the role of Part B drug prices and how they have changed over time.
BluePath Solutions, a leading health economics and value communication consulting firm, has acquired Qualia Bio.
Our landscape report provides a high-level overview of the Part B program and offers clients a comprehensive review of k...
The national average payment for each MS-DRG is calculated by multiplying the fiscal year relative weight of the MS-DRG ...